All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Tisotumab Vedotin Earns European Approval for Pretreated Recurrent/Metastatic Cervical Cancer

April 1st 2025

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer

April 1st 2025

Tovecimig plus paclitaxel improved overall response rate vs paclitaxel alone in second-line advanced biliary tract cancer.

Local Excision Possible for More Rectal Cancer Patients, Fox Chase Cancer Center Study Finds

April 1st 2025

Results from a study presented by Fox Chase Cancer Center suggest that chemotherapy followed by local excision is a promising treatment option for patients with node-negative low rectal cancer.

Pembrolizumab Plus cCRT Elicits Durable Antitumor Activity in Unresectable Stage III NSCLC

April 1st 2025

Updated KEYNOTE-799 data continued to show robust activity with pembrolizumab plus concurrent chemoradiation in unresectable stage III NSCLC.

Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma

March 31st 2025

D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.

TDI01 Demonstrates Preliminary Efficacy and Tolerability in Moderate-to-Severe cGVHD

March 31st 2025

TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.

Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma

March 31st 2025

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD

March 31st 2025

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Tislelizumab Plus Chemo Expands First-Line ESCC Treatment Paradigm

March 31st 2025

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC

March 31st 2025

Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.

Orca-T Is Associated With Retrospective OS Improvement vs Post-Transplant Cyclophosphamide in Advanced Hematologic Malignancies

March 31st 2025

Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.

Orca-T Stands Out From CD34 Grafts, Showing Lower Rates of EBV, CMV Reactivation in Hematologic Malignancies

March 31st 2025

Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.

Mayo Clinic Researchers Identify a Measurable Genetic Mutation as a Significant Predictor of Metastasis and Survival in Pancreatic Cancer

March 31st 2025

A Mayo Clinic study showed that KRAS circulating tumor DNA strongly indicates a higher risk of pancreatic cancer spread and worse survival rates.

Optimized Tandem CD19/CD20–Directed CAR T Plus ASCT Elicits Durable Responses in R/R B-Cell Lymphomas

March 31st 2025

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

First-Line Acalabrutinib Plus BR Receives CHMP Recommendation for Mantle Cell Lymphoma

March 31st 2025

CHMP recommends EU approval of acalabrutinib plus chemoimmunotherapy for untreated mantle cell lymphoma.

Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma

March 31st 2025

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

Dr Olivia on the Phase 3 QuANTUM-Wild Trial of Quizartinib in Newly Diagnosed FLT3-ITD–Negative AML

March 31st 2025

Esther Natalie Oliva, MD, discusses the rationale for the phase 3 QuANTUM-Wild trial in newly diagnosed FLT3-ITD–negative AML.

CAN-2049 Displays Potential OS Benefit in Advanced NSCLC After Inadequate Response to Checkpoint Inhibitors

March 31st 2025

CAN-2049 plus prodrug and continued immune checkpoint inhibition showed a potential OS benefit in advanced non–small cell lung cancer.

Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer

March 31st 2025

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Tislelizumab Plus Chemo Receives Positive CHMP Opinion for ES-SCLC

March 31st 2025

The EMA’s CHMP recommended the approval of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer.